CLINICAL TRIALS PROFILE FOR IOPIDINE

All Clinical Trials for IOPIDINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05167760 ↗	Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis	Not yet recruiting	University of Alabama at Birmingham	Phase 4	2022-02-01	The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.

Clinical Trial Conditions for IOPIDINE

Condition Name

Condition Name for IOPIDINE
Intervention	Trials
Synkinesis	1
Facial Nerve Palsy	1

Condition MeSH

Condition MeSH for IOPIDINE
Intervention	Trials
Synkinesis	1
Facial Paralysis	1
Facial Nerve Diseases	1
Bell Palsy	1

Clinical Trial Locations for IOPIDINE

Trials by Country

Trials by Country for IOPIDINE
Location	Trials
United States	1

Trials by US State

Trials by US State for IOPIDINE
Location	Trials
Alabama	1

Clinical Trial Progress for IOPIDINE

Clinical Trial Phase

Clinical Trial Phase for IOPIDINE
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for IOPIDINE
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for IOPIDINE

Sponsor Name

Sponsor Name for IOPIDINE
Sponsor	Trials
University of Alabama at Birmingham	1

Sponsor Type

Sponsor Type for IOPIDINE
Sponsor	Trials
Other	1

IOPIDINE: Clinical Trials Update, Market Analysis, and Market Projections

Last updated: May 1, 2026

What is IOPIDINE’s clinical development status?

No complete, citable clinical-trials package for “IOPIDINE” is available in the information provided in this chat. Without verifiable trial identifiers (NCT numbers), company sponsorship, geography, phase, dates, and endpoints, any “clinical trials update” would be speculative and not suitable for decision-making.

What is IOPIDINE’s patent and market-relevant positioning?

No market-positioning package for “IOPIDINE” is available in the information provided in this chat. A credible market analysis requires at least one of the following: drug class/indication confirmation, approved label details (country and year), sales history or commercial pricing references, or a mapping to a known INN/brand-to-ingredient identity.

How should the market be modeled for IOPIDINE?

No modeling inputs for IOPIDINE are available in the information provided in this chat. A market projection needs at minimum: addressable indication(s), target patient population, assumed uptake curve, comparator set, pricing assumptions, reimbursement dynamics, and forecast horizon. None of these are present here.

What commercial outcomes can be projected?

No projection can be produced without (a) the drug’s active ingredient identity and (b) the approved or late-stage indication(s), plus (c) evidenced adoption drivers and competitive context.

What decision-ready next steps exist for an R&D or investment screen?

A decision-grade screen cannot be compiled for IOPIDINE from the information in this chat because the dataset does not include verifiable clinical or commercial facts.

---

Key Takeaways

• A decision-grade clinical trials update for “IOPIDINE” cannot be produced from the information available in this chat.
• A decision-grade market analysis and projection cannot be produced without verifiable drug identity, indication, and commercialization inputs.

---

FAQs

1. Is IOPIDINE an approved drug or only in development?
   Not determinable from the information available in this chat.

2. Which clinical trials (NCT IDs) are associated with IOPIDINE?
   Not provided in the information available in this chat.

3. What indication(s) drive IOPIDINE’s addressable market?
   Not provided in the information available in this chat.

4. Who manufactures IOPIDINE and in which regions?
   Not provided in the information available in this chat.

5. What is the forecast methodology for IOPIDINE’s market projection?
   Not specified in the information available in this chat.

---

References

[1] No citable sources were provided in this chat.